SOURCE: Milestone Scientific, Inc.

Milestone Scientific, Inc.

November 19, 2015 07:30 ET

Milestone Scientific's Epidural & Intra-Articular Subsidiary Submits Initial Results of Clinical Trial to Premier European Pain Management Society for Publication

LIVINGSTON, NJ--(Marketwired - November 19, 2015) - Milestone Scientific's (NYSE MKT: MLSS) Epidural & Intra-Articular Subsidiary today announced that it has submitted initial results of the Company's prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure to a prestigious European pain management society in advance of this organization's annual meeting in 2016.

Milestone Scientific's Epidural & Intra-Articular Subsidiary designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space as part of acute and chronic pain management.

Successful and safe performance of epidural anesthesia or epidural injections relies on correct identification of the epidural space.

Leonard Osser, Chief Executive Officer of Milestone Scientific added, "We are pleased to have submitted initial results of this prospective, open labeled, clinical trial to one of the most prestigious European pain management societies. Compuflo® technology was designed to confirm the epidural space in real time as opposed to the current 2 step approach, which may provide significant advantages for anesthesiologists and patients. The current process requires advancing an epidural needle via loss of resistance technique and then confirming the space by injecting contrast and visualizing it under X-ray fluoroscopy. Along with other benefits, our process has the potential to significantly reduce cost and avoid radiation exposure for the patients and medical practitioners."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Tel: 212-671-1020